FDA ALERTS SOUTHERN FLORIDA PATIENTS TO POSSIBLY INADEQUATE PROSTATE CANCER TREATMENTS

The U.S. Food and Drug Administration (FDA) is alerting certain prostate cancer patients in South Florida to the possibility that they may have been given inadequate levels of the anti-cancer drug Lupron. This alert applies only to prostate cancer patients who have been treated at Urology P.A. - operated by Dr. Victor Souaid at 2100 East Sample Road, Pompano Beach, Florida.

FDA is issuing this warning because of the potentially significant health implications for prostate cancer patients who may not have received sufficient amounts of Lupron.

FDA strongly advises all patients treated for prostate cancer at Urology P.A. in Pompano Beach, Florida to contact their primary care physician immediately for evaluation and appropriate medical referral.

Prostate cancer patients who have received Lupron treatments at Urology P.A. and need additional information may call Susan Snook, Victim/Witness Coordinator for the U.S. Attorney’s Office in Fort Lauderdale, Florida, at 1-800-379-4643.

###

FDA News Page   |   FDA Home Page

Office of Public Affairs
Web page created by jch 2001-NOV-27.